Cart
sales@molnova.com
CAY10505
CAS No. 1218777-13-9
CAY10505( CAY10505 | CAY 10505 | CAY10505 )
Catalog No. M10821 CAS No. 1218777-13-9
CAY10505 is dehydroxyl of AS-252424, which is a PI3Kγ inhibitor with IC50 of 33 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 32 | In Stock |
|
| 10MG | 29 | In Stock |
|
| 25MG | 48 | In Stock |
|
| 50MG | 86 | In Stock |
|
| 100MG | 144 | In Stock |
|
| 200MG | 212 | In Stock |
|
| 500MG | 362 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCAY10505
-
NoteResearch use only, not for human use.
-
Brief DescriptionCAY10505 is dehydroxyl of AS-252424, which is a PI3Kγ inhibitor with IC50 of 33 nM.
-
DescriptionCAY10505 is dehydroxyl of AS-252424, which is a PI3Kγ inhibitor with IC50 of 33 nM.
-
In VitroA class IB PI3Kγ isoform inhibitor CAY10505 at 200 nM (IC50=30 nM) partially reduces the baicalein-induced Akt phosphorylation in neurons. The pharmacological PI3K inhibitor CAY10505 (PIK3CG) is tested on an extended panel of multiple myeloma (MM) cell lines and freshly isolated primary MM samples. MM cells are CAY10505-treated for 3 d (MM cell lines) or 5 d (primary MM cells) respectively, and survival is analysed by flow cytometry (annexin V-FITC/PI staining). Treatment of bone marrow stromal cells (BMSCs)-co-cultured primary MM samples with the PIK3CA inhibitor CAY10505 results in anti-survival effects (mean survival relative to DMSO-treated controls: CAY10505: 84±14%, tested at 10 μM).
-
In VivoAdministration of CAY10505 (0.6 mg/kg, p.o.), Losartan (25 mg/kg, p.o.), or Atorvastatin (30 mg/kg, p.o.) significantly increases serum nitrite and (or) nitrate concentrations in hypertensive rats. Acetylcholine (ACh) and Sodium nitroprusside (SNP) produce endothelium-dependent and-independent relaxation in isolated rat aortic ring precontracted with Phenylephrine (3 μM), in a dose dependent manner. Administration of CAY10505 (0.6 mg/kg,p.o.), Losartan (25 mg/kg, p.o.), or Atorvastatin (30 mg/kg, p.o.) significantly prevents hypertension-induced attenuation of ACh-induced endothelium-dependent relaxation. Deoxycorticosterone acetate salt (DOCA, 40 mg/kg, s.c.) induced hypertension markedly attenuates acetylcholine-induced endothelium-dependent relaxation, but does not affect SNP-induced endotheliumindependent relaxation.
-
SynonymsCAY10505 | CAY 10505 | CAY10505
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3Kγ
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1218777-13-9
-
Formula Weight289.28
-
Molecular FormulaC14H8FNO3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 58 mg/mL (200.49 mM)
-
SMILESO=C(NC/1=O)SC1=C\C2=CC=C(C3=CC=C(F)C=C3)O2
-
Chemical Name(E)-5-((5-(4-fluorophenyl)furan-2-yl)methylene)thiazolidine-2,4-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tyagi S, Sharma S, Budhiraja RD.Can J Physiol Pharmacol. 2012 Jul;90(7):881-5.
molnova catalog
related products
-
Splitomicin
Splitomicin (IC50 of 60 μM), a specific inhibitor of NAD(+)-dependent histone deacetylase Sir2p, displays a high activity in a cell-based assay.
-
ETP-46321
ETP-46321 is a potent, selective, orally bioavailable dual PI3K α/δ inhibitor with IC50 of 2.3/14.2 nM.
-
STX-478
STX-478 is an orally active and selective PI3Kα inhibitor that penetrates the blood-brain barrier and has anticancer activity to inhibit tumor growth.STX-478 is indicated for the study of breast cancer and other cancers.
